FGF23 promotes myocardial fibrosis in mice through activation of β-catenin

Oncotarget

Volumn 7, Issue 40, 2016, Pages 64649-64664

  Hao, Huixin ^a   Li, Xixian ^a   Li, Qingman ^a   Lin, Hairuo ^a   Chen, Zhenhuan ^a   Xie, Jiahe ^a   Xuan, Wanling ^a   Liao, Wangjun ^a   Bin, Jianping ^a   Huang, Xiaobo ^a   Kitakaze, Masafumi ^a,b   Liao, Yulin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Fibroblast growth factor 23; Ischemia reperfusion; Myocardial fibrosis; Pathology Section; TGF ; catenin

Indexed keywords

ANGIOTENSIN II; BETA CATENIN; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FRACTALKINE; PHENYLEPHRINE; PROCOLLAGEN; PROCOLLAGEN I; PROCOLLAGEN III; RECOMBINANT FIBROBLAST GROWTH FACTOR 23; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; COLLAGEN; FGFR4 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; SMALL INTERFERING RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA CATENIN GENE; CELL PROLIFERATION; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; FGF23 GENE; FIBROBLAST; GENE; GENE ACTIVATION; GENE FUNCTION; GENE SILENCING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REPERFUSION INJURY; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; CELL CULTURE; DEPENDOPARVOVIRUS; FIBROSIS; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; BETA CATENIN; CELLS, CULTURED; COLLAGEN; DEPENDOVIRUS; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; FIBROSIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; PHENYLEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; REPERFUSION INJURY; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84994083573     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11623     Document Type: Article

References (35)

1. Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res. 2012; 318(9):1040-1048.
2. Itoh N and Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol. 2013; 4:247.
3. Ezumba I, Quarles LD and Kovesdy CP. [FGF23 and the heart]. G Ital Nefrol. 2014; 31(6).
4. Olauson H and Larsson TE. FGF23 and Klotho in chronic kidney disease. Curr Opin Nephrol Hypertens. 2013; 22(4):397-404.
5. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W and Quarles LD. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012; 7(9):e44161.
6. Mirza MA, Larsson A, Melhus H, Lind L and Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009; 207(2):546-551.
7. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens. 2012; 21(4):369-375.
8. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11):4393-4408.
9. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C and Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119(19):2545-2552.
10. Yan L and Bowman MA. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23. Inflamm Cell Signal. 2014; 1(5).
11. Zhou L, Li Y, Zhou D, Tan RJ and Liu Y. Loss of Klotho contributes to kidney injury by derepression of Wnt/betacatenin signaling. J Am Soc Nephrol. 2013; 24(5):771-785.
12. Ayca B, Sahin I, Kucuk SH, Akin F, Kafadar D, Avsar M, Avci, II, Gungor B, Okuyan E and Dinckal MH. Increased Transforming Growth Factor-beta Levels Associated With Cardiac Adverse Events in Hypertrophic Cardiomyopathy. Clin Cardiol. 2015; 38(6):371-377.
13. Khan S, Joyce J, Margulies KB and Tsuda T. Enhanced bioactive myocardial transforming growth factor-beta in advanced human heart failure. Circ J. 2014; 78(11):2711-2718.
14. Nagalingam RS, Sundaresan NR, Noor M, Gupta MP, Solaro RJ and Gupta M. Deficiency of cardiomyocytespecific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor beta (TGFbeta1)-dependent paracrine mechanism. J Biol Chem. 2014; 289(39):27199-27214.
15. Guo Y, Xiao L, Sun L and Liu F. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res. 2012; 61(4):337-346.
16. Lam AP and Gottardi CJ. beta-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol. 2011; 23(6):562-567.
17. Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, Bin J and Kitakaze M. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res. 2011; 92(3):385-393.
18. Xuan W, Wu B, Chen C, Chen B, Zhang W, Xu D, Bin J and Liao Y. Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine. Crit Care Med. 2012; 40(11):3026-3033.
19. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, et al. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015; 22(6):1020-1032.
20. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA and Ix JH. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010; 152(10):640-648.
21. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG and Floege J. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015; 132(1):27-39.
22. Andrukhova O, Slavic S, Odorfer KI and Erben RG. Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23. J Bone Miner Res. 2015; 30(10):1831-1839.
23. 1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Aktmediated cardiac fibrosis in experimental uremia. J Mol Cell Cardiol. 2015; 85:249-261.
24. Muller-Brunotte R, Kahan T, Lopez B, Edner M, Gonzalez A, Diez J and Malmqvist K. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens. 2007; 25(9):1958-1966.
25. Liao Y, Bin J, Asakura M, Xuan W, Chen B, Huang Q, Xu D, Ledent C, Takashima S and Kitakaze M. Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice. Eur Heart J. 2012; 33(24):3124-3133.
26. Tan RJ, Zhou D, Zhou L and Liu Y. Wnt/beta-catenin signaling and kidney fibrosis. Kidney Int Suppl (2011). 2014; 4(1):84-90.
27. Duan J, Gherghe C, Liu D, Hamlett E, Srikantha L, Rodgers L, Regan JN, Rojas M, Willis M, Leask A, Majesky M and Deb A. Wnt1/betacatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. Embo j. 2012; 31(2):429-442.
28. Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstadt H, Wolf M, Faul C and Brand M. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant. 2014; 29(11):2028-2035.
29. 1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/Ets-1 signalling pathway. J Cell Mol Med. 2014; 18(11):2311-2320.
30. Wei X, Wu B, Zhao J, Zeng Z, Xuan W, Cao S, Huang X, Asakura M, Xu D, Bin J, Kitakaze M and Liao Y. Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9. Circulation. 2015; 131(17):1506-1517; discussion 1517.
31. Zeng Z, Shen L, Li X, Luo T, Wei X, Zhang J, Cao S, Huang X, Fukushima Y, Bin J, Kitakaze M, Xu D and Liao Y. Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clin Sci (Lond). 2014; 127(7):435-448.
32. Luo T, Chen B, Zhao Z, He N, Zeng Z, Wu B, Fukushima Y, Dai M, Huang Q, Xu D, Bin J, Kitakaze M and Liao Y. Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function. Basic Res Cardiol. 2013; 108(3):342.
33. Shen L, Chen C, Wei X, Li X, Luo G, Zhang J, Bin J, Huang X, Cao S, Li G and Liao Y. Overexpression of ankyrin repeat domain 1 enhances cardiomyocyte apoptosis by promoting p53 activation and mitochondrial dysfunction in rodents. Clin Sci (Lond). 2015; 128(10):665-678.
34. Li X, Zeng Z, Li Q, Xu Q, Xie J, Hao H, Luo G, Liao W, Bin J, Huang X and Liao Y. Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. Oncotarget. 2015; 6(22):18829-18844. doi: 10.18632/oncotarget.4774.
35. Luo G, Li Q, Zhang X, Shen L, Xie J, Zhang J, Kitakaze M, Huang X and Liao Y. Ablation of C/EBP homologous protein increases the acute phase mortality and doesn't attenuate cardiac remodeling in mice with myocardial infarction. Biochem Biophys Res Commun. 2015; 464(1):201-207.